SION Sionna Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why SION matters now
Sionna Therapeutics, Inc. (SION) is a US stock in Healthcare. The latest InvestLog snapshot shows $44.94 with +2.14% on the session and $2.03B in market capitalization; recent performance reads 1-month -1.01% and YTD -9.33%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-26.8M, and EPS of $-0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.3%.
The latest indexable market news headline is "Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $54.00; recent insider activity includes Booth Bruce filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.81
P/S
0.00
EV/EBITDA
-20.10
DCF Value
$1.23
FCF Yield
-4.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-27.3%
ROA
-28.1%
ROIC
-33.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-26.8M | $-0.60 |
| Q4 2025 | $0.00 | $-20.4M | $-0.46 |
| FY 2025 | $0.00 | $-75.3M | $-1.88 |
| Q3 2025 | $0.00 | $-20.3M | $-0.46 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$54.00
Target (Median)
$54.00
Target Range
$50.00 - $58.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.29
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.